Benzinga | Sep 10, 2021 07:36PM EDT

B of A Securities Initiates Coverage On Nektar Therapeutics with Neutral Rating, Announces Price Target of $18

B of A Securities analyst Greg Harrison initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Neutral rating and announces Price Target of $18.